



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Azintuxizumab

Cat. No.:	HY-P99453
CAS No.:	1826819-57-1
Target:	ADC Antibody; CD3
Pathway:	Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Azintuxizumab (ABBV-383; PR-1471272) is an IgG4 T cell-engaging bispecific mAb (T-BsAb) targeting B cell maturation antigen (BCMA). Azintuxizumab has the potential to be used in relapsed/refractory multiple myeloma (RRMM) research. Azintuxizumab is composed of two heavy chains and one light chain: the heavy chain (human CD319 antigen and human-mouse monoclonal PR-1471272, respectively) and the light chain (human-mouse monoclonal PR-1471272) are connected by disulfide bonds and can bind to CD3 (Kd=1.3  $\mu$ M). Azintuxizumab can form ADC conjugates with derivatives of hemistarlin (HY-117371)<sup>[1]</sup>.

### REFERENCES

[1]. D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen  $\times$  CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. *J Clin Oncol*. 2022 Nov 1;40(31):3576-3586.

[2]. Hemiastarlin derivative and antibody-drug conjugates including same. World Intellectual Property Organization, WO2019031615 A1 2019-02-14 .

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA